Literature DB >> 7159889

Experimental percutaneous renal embolization using BCG-saturated gelfoam.

K C Wright, C S Soo, S Wallace, M W McDonald, A Ayala.   

Abstract

Adult mongrel dogs (20-25 kg) were used to evaluate the administration of Bacillus Calmette-Guerin (BCG) in conjunction with total renal embolization for possible application in the management of metastatic renal cell carcinoma (RCC). Kidneys were surgically removed at 1, 2, and 3 weeks postembolization, examined grossly and microscopically, and then compared with kidneys embolized in the same manner without BCG. The procedure stimulated the reticuloendothelial system more than did renal embolization alone, and although a high dose (6 X 10(8) organisms) of BCG was administered, no complications were encountered. These results warrant a clinical trial of this technique in patients with advanced RCC.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159889     DOI: 10.1007/bf02565408

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  23 in total

1.  Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice.

Authors:  P J Lachmann; K Sikora
Journal:  Nature       Date:  1978-02-02       Impact factor: 49.962

Review 2.  BCG and cancer (first of two parts).

Authors:  R C Bast; B Zbar; T Borsos; H J Rapp
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

3.  Spontaneous regression of pulmonary metastases following palliative nephrectomy. Case report.

Authors:  M Markewitz; D A Taylor; R J Veenema
Journal:  Cancer       Date:  1967-07       Impact factor: 6.860

Review 4.  The regulatory role of macrophages in antigenic stimulation.

Authors:  E R Unanue
Journal:  Adv Immunol       Date:  1972       Impact factor: 3.543

5.  Cell-mediated immunity to tumor antigens in patients with renal cell carcinoma.

Authors:  K B Cummings; J B Peter; J J Kaufman
Journal:  J Urol       Date:  1973-07       Impact factor: 7.450

6.  The role of embolization and nephrectomy in the treatment of metastatic renal carcinoma.

Authors:  D A Swanson; S Wallace; D E Johnson
Journal:  Urol Clin North Am       Date:  1980-10       Impact factor: 2.241

7.  BCG immunotherapy of metastatic adenocarcinoma of the kidney.

Authors:  D Eidinger; A Morales
Journal:  Natl Cancer Inst Monogr       Date:  1978-12

Review 8.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

9.  Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.

Authors:  M J Mastrangelo; R E Bellet; J Berkelhammer; W H Clark
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

10.  BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells.

Authors:  R W Baldwin; M V Pimm
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640

View more
  1 in total

1.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.